Genome Publications
https://doi.org/10.61096/978-81-981372-2-7_11

Chapter 11

Oncology Pharmacology: Targeted and Immune Therapies

Dr. Shaktiprasad Pradhan
Professor and Principal, KRIMS, Bhubaneswar, Odisha
Prof. Pramila Kumari Misra
Emeritus Scientist (CSIR), Centre of Studies in Surface Science and Technology, School of Chemistry, Sambalpur University, Jyoti Vihar, Odisha
Minakshi Kumari Panda
Associate Professor, KRIMS, Bhubaneswar, Odisha

Abstract: The landscape of oncology pharmacology has undergone a profound transformation over the past two decades, driven by advances in molecular biology, immunology, and pharmacogenomics. From traditional cytotoxic chemotherapy to precision-targeted and immune-based approaches, therapeutic interventions for cancer are increasingly personalized, effective, and durable. This chapter provides a comprehensive overview of the pharmacologic modalities used in modern cancer treatment. Beginning with a foundational understanding of cancer biology and the evolution of cytotoxic chemotherapy, it delves into molecularly targeted therapies such as tyrosine kinase inhibitors (TKIs) and poly(ADP-ribose) polymerase (PARP) inhibitors. The development and application of monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors are examined in detail, alongside novel platforms such as CAR-T cell therapy and bispecific antibodies. The chapter also explores the growing role of pharmacogenomics in guiding treatment selection and tailoring interventions. Finally, it addresses the persistent challenges in oncology pharmacology, including drug resistance, cost constraints, and equitable access. Through an integration of mechanistic insights, clinical applications, and emerging trends, this chapter aims to equip readers with a nuanced understanding of contemporary cancer pharmacotherapy.

Keywords: Oncology pharmacology, targeted therapy, immune checkpoint inhibitors, CAR-T cell therapy, pharmacogenomics

Citation: Shaktiprasad Pradhan, Pramila Kumari Misra, Minakshi Kumari Panda. Oncology Pharmacology: Targeted and Immune Therapies. *Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems.* Genome Publications. 2025; Pp112-121. https://doi.org/10.61096/978-81-981372-2-7_11

11.0 INTRODUCTION

The evolution of oncology pharmacology mirrors the scientific and technological revolutions that have shaped modern medicine. Historically reliant on broadly cytotoxic agents, cancer therapy has progressively incorporated biologically targeted treatments and immunomodulatory approaches. This shift reflects a deeper understanding of cancer as a disease driven by complex genetic, epigenetic, and immunologic dysregulation. The development of therapies that target specific molecular pathways or harness the immune system has led to more effective and often less toxic treatment options. Innovations in genomic profiling, bioinformatics, and cell engineering have further enabled clinicians to design personalized therapeutic regimens that match the biological features of a patient's tumor. However, despite the promise of these advances, challenges such as treatment resistance, high costs, and limited accessibility continue to pose significant barriers. This chapter explores the key pharmacologic modalities currently employed in oncology, emphasizing their mechanisms, clinical applications, limitations, and future directions. Through this lens, we will understand how a deeper knowledge of cancer biology is translating into increasingly precise, effective, and adaptable treatments.

11.1 Cytotoxic Chemotherapy

Cytotoxic chemotherapy remains a foundational element of cancer treatment, particularly in the management of hematologic malignancies and advanced solid tumors. These agents exert their antineoplastic effects by interfering with rapidly dividing cells, exploiting the fact that cancer cells proliferate more aggressively than most normal cells. However, this non-specificity also underlies many of the toxicities associated with traditional chemotherapy.

11.1.1 Cell Cycle-Specific Agents

Cytotoxic agents can be classified based on whether their activity is cell cycle–specific or non-specific. Cell cycle–specific agents act at defined stages of cell division. For instance, antimetabolites such as 5-fluorouracil (5-FU) and methotrexate are S-phase specific, interfering with DNA synthesis. Mitotic inhibitors like paclitaxel and vincristine act during the M phase, disrupting microtubule function and preventing mitosis. These agents are particularly effective in tumors with high proliferative indices, such as leukemias and lymphomas [1,2]. However, their efficacy depends on a sufficient proportion of tumor cells being in the vulnerable phase of the cell cycle during drug exposure. The timing of administration and scheduling (e.g., pulse dosing vs continuous infusion) is therefore critical to maximize therapeutic benefit while limiting toxicity [3].

Table 11.1: Major Classes of Cytotoxic Chemotherapy

Class	Mechanism of Action	Cell Cycle Phase	Examples
Antimetabolites	Inhibit DNA/RNA synthesis	S-phase specific	5-Fluorouracil (5-FU), Methotrexate
Mitotic Inhibitors	Inhibit microtubule formation	M-phase specific	Paclitaxel, Vincristine
Alkylating Agents	Crosslink DNA, leading to strand breaks	Cell cycle–nonspecific	Cyclophosphamide, Cisplatin

Anthracyclines	Intercalate DNA and inhibit topoisomerase II	Cell cycle–nonspecific	Doxorubicin, Epirubicin
Topoisomerase Inhibitors	Block DNA unwinding and replication	S-phase or G2 phase	Irinotecan, Etoposide

11.1.2 Dose-Limiting Toxicities

Despite their effectiveness, cytotoxic agents carry a narrow therapeutic index and are associated with significant adverse effects. Myelosuppression, characterized by neutropenia, anemia, and thrombocytopenia, is a common dose-limiting toxicity that can predispose patients to life-threatening infections and bleeding. Mucositis, particularly with methotrexate and 5-FU, causes painful inflammation and ulceration of the mucous membranes, impacting nutrition and quality of life. Alopecia, though reversible, is a distressing side effect that affects patient adherence and psychosocial well-being. Other notable toxicities include cardiotoxicity with anthracyclines, nephrotoxicity with cisplatin, and neurotoxicity with oxaliplatin or vincristine [4,5]. Efforts to mitigate these effects include dose adjustments, supportive care interventions (e.g., granulocyte colony-stimulating factors), and the use of protective agents such as dexrazoxane for cardioprotection.

While cytotoxic chemotherapy is increasingly supplemented or replaced by targeted and immunotherapeutic agents, it remains indispensable in many treatment protocols, particularly where rapid cytoreduction is needed or when tumors lack actionable molecular targets.

11.2 Tyrosine Kinase Inhibitors (TKIs)

The introduction of tyrosine kinase inhibitors has revolutionized the treatment of various cancers by providing a means to disrupt specific intracellular signaling pathways essential for tumor growth and survival. Tyrosine kinases, which function as molecular switches in growth factor signaling cascades, are often dysregulated in cancer through mutations, amplifications, or translocations.

11.2.1 EGFR, VEGFR, ALK, BCR-ABL Inhibitors

TKIs targeting the epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), anaplastic lymphoma kinase (ALK), and BCR-ABL fusion protein have demonstrated substantial clinical benefit across diverse tumor types. For instance, EGFR inhibitors like erlotinib and osimertinib are effective in non-small cell lung cancer (NSCLC) with EGFR mutations [6]. Similarly, ALK inhibitors such as crizotinib and alectinib offer durable responses in ALK-rearranged NSCLC [7]. Imatinib, the first successful TKI, transformed the prognosis of chronic myeloid leukemia (CML) by targeting BCR-ABL, a constitutively active tyrosine kinase resulting from the Philadelphia chromosome translocation [8]. Inhibitors of VEGFR such as sunitinib and sorafenib interfere with tumor angiogenesis, proving valuable in renal cell carcinoma and hepatocellular carcinoma.

However, resistance to TKIs often emerges through secondary mutations, bypass signaling, or pharmacokinetic alterations. For example, the T790M mutation in EGFR confers resistance to first-generation inhibitors but can be overcome with third-generation agents like osimertinib [9]. The sequential use of TKIs tailored to resistance mechanisms represents a dynamic model of precision oncology, but continual monitoring and biomarker testing are essential.

As the development of TKIs expands to new targets and combinatorial strategies, they are increasingly integrated into frontline regimens, offering improved tolerability and disease control compared to conventional chemotherapy.

11.3 PARP Inhibitors and Synthetic Lethality

Poly(ADP-ribose) polymerase (PARP) inhibitors represent a class of targeted therapies that exploit the concept of synthetic lethality selectively killing tumor cells harboring specific genetic deficiencies, such as BRCA1 or BRCA2 mutations. PARP enzymes are essential for repairing single-strand DNA breaks through the base excision repair pathway. In cells deficient in homologous recombination repair (HRR) a key pathway mediated by BRCA proteins the inhibition of PARP leads to the accumulation of DNA damage and ultimately cell death.

Table 11.2: Key Targeted Therapies (TKIs and PARP Inhibitors)

Drug Class	Target/Mechanism	Indications	Examples
Tyrosine Kinase Inhibitors (TKIs)	Block growth factor receptor pathways (EGFR, VEGFR, ALK, BCR-ABL)	NSCLC, CML, Renal Cell Carcinoma	Erlotinib, Osimertinib, Imatinib, Sunitinib
PARP Inhibitors	Inhibit DNA repair via PARP trapping	BRCA-mutated ovarian, breast, and prostate cancers	Olaparib, Niraparib, Rucaparib

11.3.1 DNA Repair Inhibition

Olaparib was the first PARP inhibitor approved by regulatory agencies for BRCA-mutated ovarian and breast cancers, with subsequent expansion to prostate and pancreatic cancers. Other agents such as niraparib, rucaparib, and talazoparib have been developed and demonstrate efficacy in both germline and somatic BRCA-mutated tumors as well as in cancers exhibiting homologous recombination deficiency (HRD) [10]. These drugs trap PARP1 at sites of DNA damage, preventing repair and leading to replication fork collapse, a mechanism distinct from mere enzymatic inhibition.

Clinical trials such as SOLO1 and PRIMA have demonstrated progression-free survival benefits of PARP inhibitors as maintenance therapy following platinum-based chemotherapy in ovarian cancer patients with BRCA mutations or HRD [11,12]. Importantly, the efficacy of these agents extends beyond BRCA mutations, suggesting a broader role in tumors with “BRCAness” phenotypes.

Resistance to PARP inhibitors can develop through restoration of homologous recombination via secondary BRCA mutations, loss of PARP1 expression, or upregulation of drug efflux pumps. Strategies to overcome resistance include combination therapies with angiogenesis inhibitors, immune checkpoint inhibitors, and DNA damage response (DDR) inhibitors such as ATR or WEE1 kinase inhibitors [13].

The emergence of PARP inhibitors highlights the paradigm of targeting tumor vulnerabilities created by specific genetic alterations and has paved the way for further exploration of synthetic lethality in cancer therapy.

11.4 Monoclonal Antibodies and Antibody-Drug Conjugates (ADCs)

Monoclonal antibodies (mAbs) have significantly advanced the precision and selectivity of cancer treatment by targeting specific antigens on tumor cells. These biologics can act through multiple mechanisms including direct inhibition of receptor signaling, immune-mediated cytotoxicity, and delivery of cytotoxic payloads via antibody-drug conjugates (ADCs).

11.4.1 Trastuzumab, Rituximab, ADCs

Trastuzumab, a humanized monoclonal antibody targeting HER2, transformed the treatment landscape of HER2-positive breast and gastric cancers. By inhibiting HER2 signaling and inducing

antibody-dependent cellular cytotoxicity (ADCC), trastuzumab improves survival when used in combination with chemotherapy [14]. Resistance, however, can occur via HER2 shedding, activation of downstream PI3K/AKT signaling, or compensatory receptor upregulation. Strategies to address resistance include combining trastuzumab with pertuzumab (a HER2 dimerization inhibitor) or using ADCs like trastuzumab emtansine (T-DM1), which delivers the cytotoxic agent DM1 directly to HER2-expressing cells [15].

Rituximab, targeting CD20 on B cells, revolutionized the management of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It mediates tumor cell death through complement activation, ADCC, and direct apoptosis. Its success has led to the development of biosimilars and next-generation anti-CD20 antibodies such as obinutuzumab with enhanced efficacy [16].

ADCs combine the specificity of antibodies with the potency of cytotoxins. Examples include brentuximab vedotin for CD30-positive lymphomas and enfortumab vedotin for urothelial carcinoma. The design of ADCs involves optimized linker chemistry to ensure stability in circulation and efficient release of the cytotoxic payload within the tumor microenvironment [17].

Monoclonal antibody therapy continues to expand with bispecific formats, immune-activating antibodies, and Fc-engineered variants, marking a growing frontier in targeted cancer therapy.

11.5 Immune Checkpoint Inhibitors

The immune system's ability to detect and eliminate cancer is often thwarted by tumor-mediated immune evasion mechanisms. Immune checkpoint inhibitors (ICIs) have revolutionized oncology by unleashing cytotoxic T-cell activity against tumor cells through blockade of inhibitory receptors.

Table 11.3: Immune-Based Therapies (Checkpoint Inhibitors)

Target	Mechanism	Examples	Cancer Types
PD-1	Blocks PD-1 receptor on T-cells	Nivolumab, Pembrolizumab	Melanoma, NSCLC, RCC
PD-L1	Blocks PD-L1 ligand on tumor cells	Atezolizumab, Durvalumab	NSCLC, Urothelial carcinoma
CTLA-4	Blocks inhibitory CTLA-4 receptor on T-cells	Ipilimumab	Melanoma, Combination regimens

11.5.1 PD-1, PD-L1, CTLA-4 Blockade

Programmed death-1 (PD-1) and its ligand PD-L1, as well as cytotoxic T-lymphocyte antigen-4 (CTLA-4), are key inhibitory receptors that modulate T-cell activation. Tumors exploit these checkpoints to suppress immune responses. Antibodies such as nivolumab and pembrolizumab (anti-PD-1), atezolizumab (anti-PD-L1), and ipilimumab (anti-CTLA-4) disrupt these interactions, restoring T-cell function and promoting antitumor immunity [18].

Checkpoint inhibitors have demonstrated durable responses in a variety of malignancies, including melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, and Hodgkin lymphoma. In advanced melanoma, combination therapy with ipilimumab and nivolumab has shown superior response rates compared to monotherapy, albeit with increased toxicity [19].

Immune-related adverse events (irAEs) such as colitis, pneumonitis, hepatitis, endocrinopathies, and dermatitis arise from immune activation against normal tissues. These are

managed with corticosteroids and immunosuppressants, and early recognition is critical to avoid severe outcomes [20].

Biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and mismatch repair deficiency (dMMR) are used to predict response, although none are universally reliable. Research into better predictive biomarkers and combination regimens (e.g., with chemotherapy, radiation, or other ICIs) is ongoing to broaden the utility of immune checkpoint blockade.



Figure 11.1: Mechanism of Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4 Blockade)

11.6 CAR-T Cell Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy represents a milestone in personalized cancer immunotherapy. By engineering a patient's own T cells to recognize and attack tumor-specific antigens, CAR-T therapy offers a highly specific and potent approach to cancer treatment.

11.6.1 Autologous T-Cell Engineering

The process of CAR-T therapy involves isolating a patient's T cells, genetically modifying them ex vivo to express a synthetic receptor that binds to a tumor antigen (e.g., CD19), expanding the modified cells, and reinfusing them into the patient. The CAR construct typically consists of an extracellular antigen-recognition domain, a transmembrane region, and intracellular signaling domains (CD3ζ with co-stimulatory signals like CD28 or 4-1BB) to activate T cells upon antigen engagement [21].

FDA-approved CAR-T therapies include tisagenlecleucel and axicabtagene ciloleucel for B-cell acute lymphoblastic leukemia (ALL) and large B-cell lymphomas. These therapies have demonstrated high response rates and long-term remissions in relapsed/refractory settings [22].

However, CAR-T therapy is associated with serious toxicities. Cytokine release syndrome (CRS), marked by fever, hypotension, and organ dysfunction, results from massive cytokine secretion upon T-cell activation. Tocilizumab (anti-IL-6 receptor antibody) and corticosteroids are used for management. Neurotoxicity, termed immune effector cell-associated neurotoxicity syndrome (ICANS), can range from confusion to seizures and cerebral edema, necessitating close monitoring and supportive care [23].

Challenges in CAR-T therapy include manufacturing complexity, high cost, limited efficacy in solid tumors due to immunosuppressive tumor microenvironments, and antigen escape. Ongoing innovations involve universal ("off-the-shelf") CAR-Ts, dual-antigen targeting, armored CARs with cytokine expression, and integration with checkpoint blockade.

11.7 Bispecific Antibodies and Cancer Vaccines

As cancer immunotherapy continues to evolve, bispecific antibodies and cancer vaccines have emerged as innovative modalities designed to engage the immune system in more targeted and dynamic ways. These approaches aim to enhance T-cell activation, broaden antigen recognition, and overcome immune evasion strategies employed by tumors.

11.7.1 Dual-Target Therapies

Bispecific antibodies (bsAbs) are engineered molecules capable of simultaneously binding two different antigens often one on a tumor cell and the other on an immune effector cell such as a T lymphocyte. Blinatumomab, the first FDA-approved bsAb, targets CD19 on B cells and CD3 on T cells, facilitating cytotoxic synapse formation and direct T-cell–mediated killing of malignant B cells in acute lymphoblastic leukemia (ALL) [24].

The success of blinatumomab has led to the development of several other bsAbs targeting diverse tumor types and antigens, including CD20, HER2, and BCMA (B-cell maturation antigen). These agents offer advantages such as MHC-independent recognition and rapid immune engagement, making them particularly attractive in refractory or relapsed hematologic malignancies. However, cytokine release syndrome and neurotoxicity remain notable challenges, necessitating vigilant monitoring during administration [25].

Cancer vaccines aim to stimulate an adaptive immune response against tumor-associated antigens (TAAs). These may include peptide-based, dendritic cell–based, or mRNA-based vaccines. Personalized neoantigen vaccines, generated using tumor sequencing data, are showing promise in early-phase clinical trials by directing immune responses toward unique tumor mutations [26]. The success of mRNA platforms in COVID-19 vaccines has accelerated interest in their oncology applications.

Despite their theoretical appeal, cancer vaccines have faced obstacles such as immune tolerance, tumor heterogeneity, and immunosuppressive tumor microenvironments. Combinatorial strategies with checkpoint inhibitors, adjuvants, and novel delivery systems are being explored to improve immunogenicity and clinical outcomes.

11.8 Pharmacogenomics in Oncology

Pharmacogenomics the study of how genetic variations influence drug response has become a cornerstone of precision oncology. The identification of actionable mutations and molecular signatures enables personalized treatment decisions that enhance efficacy and minimize toxicity.

11.8.1 Companion Diagnostics

Companion diagnostics are laboratory tests developed to identify biomarkers predictive of therapeutic response or resistance. These tools guide oncologists in selecting targeted agents tailored to the molecular profile of an individual's tumor. For instance, Oncotype DX is used in early-stage hormone receptor–positive breast cancer to estimate the risk of recurrence and determine the benefit of chemotherapy. Patients with low recurrence scores may safely avoid cytotoxic therapy, sparing them from unnecessary toxicity [27].

Next-generation sequencing (NGS) platforms such as FoundationOne CDx provide comprehensive genomic profiling of solid tumors, identifying mutations in hundreds of genes simultaneously. This approach allows for detection of multiple actionable targets including EGFR, ALK, ROS1, RET, NTRK, BRAF, and others and facilitates enrollment in biomarker-driven clinical trials [28].

Pharmacogenomic testing also informs dosing decisions for cytotoxic drugs. For example, polymorphisms in *DPYD* can predict severe toxicity to fluoropyrimidines like 5-FU and capecitabine, guiding dose adjustments. Similarly, *UGT1A1* variants influence irinotecan metabolism and the risk of neutropenia [29].

As genomic medicine becomes more accessible and cost-effective, integrating pharmacogenomics into routine oncology practice promises to further personalize cancer care, enhance therapeutic outcomes, and reduce unnecessary interventions.

11.9 Oncology Drug Development Challenges

Despite unprecedented advances in molecular oncology and immunotherapy, the development and implementation of new anticancer agents face substantial challenges related to cost, access, regulatory complexity, and therapeutic resistance.

11.9.1 Cost, Access, and Resistance

The cost of developing a single oncology drug can exceed USD 2 billion, encompassing preclinical research, clinical trials, regulatory approval, and post-marketing surveillance. High pricing of novel agents such as CAR-T therapies or PARP inhibitors places significant financial strain on healthcare systems and may limit patient access, particularly in low- and middle-income countries [30].

Intellectual property rights, market exclusivity, and complex manufacturing processes contribute to elevated drug costs. Health technology assessments (HTAs) and cost-effectiveness analyses are increasingly used to guide coverage decisions, but disparities in global regulatory frameworks and reimbursement policies remain a barrier to equitable access [31].

Resistance to therapy continues to undermine long-term outcomes, even in the era of targeted and immune-based treatments. Tumor heterogeneity, clonal evolution, and adaptive signaling allow cancer cells to evade initial therapeutic pressures. Acquired mutations, epigenetic alterations, and changes in drug transport or metabolism further compound resistance [32].

Addressing these challenges requires a multipronged strategy: promoting drug repurposing, accelerating clinical trial designs through adaptive and basket trial models, supporting biosimilar development, and ensuring integration of real-world evidence into regulatory and policy decisions. Collaborative efforts between academia, industry, and public health agencies are essential to create sustainable and patient-centric oncology care models.

11.10 CONCLUSION

The field of oncology pharmacology has undergone a profound transformation, transitioning from the era of nonspecific cytotoxic agents to a new paradigm defined by molecular precision and immune modulation. Each class of therapeutic agent from traditional chemotherapeutics and tyrosine kinase inhibitors to monoclonal antibodies, PARP inhibitors, and immune checkpoint blockers reflects a deepening understanding of cancer biology and the diverse mechanisms by which tumors proliferate, evade immunity, and resist treatment. The integration of genomic data and companion diagnostics has enabled clinicians to tailor therapy to individual tumor profiles, thereby improving response rates and minimizing unnecessary toxicity. Notwithstanding these advances, substantial challenges remain. Tumor heterogeneity, clonal evolution, and acquired resistance continue to undermine the durability of responses. Immune-based therapies, while revolutionary, are associated with complex adverse events and variable efficacy across tumor types. Moreover, the high cost of novel therapies raises significant concerns about global access, affordability, and equitable care. These limitations underscore the necessity of ongoing innovation not only in drug discovery but also in trial design, regulatory policy, and systems-level implementation of precision oncology.

Looking forward, the future of cancer pharmacotherapy will likely be shaped by the convergence of multi-omic profiling, artificial intelligence–guided decision-making, and integrative immuno-oncology. Newer therapeutic modalities such as bispecific antibodies, cancer vaccines, CAR-T and CAR-NK cell therapies, and synthetic lethality–based strategies are rapidly advancing toward clinical maturity. Importantly, multidisciplinary collaboration among oncologists, pharmacologists, molecular biologists, and bioinformaticians will be essential to realize the full potential of these interventions. In summary, oncology pharmacology now resides at the forefront of personalized medicine, offering unprecedented opportunities to transform cancer into a controllable, if not curable, condition. Continued research, equitable access, and a commitment to scientific rigor will be paramount in achieving sustained progress in the fight against cancer.

REFERENCES

1. World Health Organization. Global Health Estimates 2023.
2. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. *Pathog Glob Health.* 2015;109(7):309–318.
3. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. *Clin Microbiol Rev.* 2010; 23(1):160–201.
4. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. *Nat Rev Microbiol.* 2014;12(1):35–48.
5. Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. *Ann N Y Acad Sci.* 2015; 1354:12–31.
6. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther Adv Drug Saf.* 2014;5(6):229–241.
7. Beigel JH, et al. Remdesivir for the treatment of Covid-19 final report. *N Engl J Med.* 2020;383(19):1813–1826.
8. Whitley RJ, Kimberlin DW. Herpes simplex encephalitis: children and adolescents. *Semin Pediatr Infect Dis.* 2005;16(1):17–23.
9. Gunthard HF, et al. Antiretroviral therapy for HIV infection in adults. *JAMA.* 2016;316(2):191–210.

10. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. *Science.* 2017; 355(6330): 1152–1158.
11. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med.* 2018; 379:2495–2505.
12. González-Martín A, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med.* 2019;381(25):2391–2402.
13. O'Connor MJ. Targeting the DNA damage response in cancer. *Mol Cell.* 2015;60(4):547–560.
14. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med.* 2001;344(11):783–792.
15. Krop IE, et al. Trastuzumab emtansine vs. lapatinib plus capecitabine for HER2-positive advanced breast cancer. *Lancet Oncol.* 2014;15(4):397–406.
16. Coiffier B, et al. Long-term outcome of patients in the LNH-98.5 trial. *J Clin Oncol.* 2010;28(27):4527–4533.
17. Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. *Pharmacol Ther.* 2018;181:126–142.
18. Topalian SL, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. *N Engl J Med.* 2012;366(26):2443–2454.
19. Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med.* 2015;373(1):23–34.
20. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med.* 2018;378(2):158–168.
21. June CH, et al. CAR T cell immunotherapy for human cancer. *Science.* 2018;359(6382):1361–1365.
22. Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med.* 2017;377(26):2531–2544.
23. Lee DW, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood.* 2014;124(2):188–195.
24. Topp MS, et al. Targeted therapy with the T-cell–engaging antibody blinatumomab. *N Engl J Med.* 2015;373(26):2531–2541.
25. Labrijn AF, Janmaat ML, Reichert JM, Parren PW. Bispecific antibodies: a mechanistic review of the pipeline. *Nat Rev Drug Discov.* 2019;18(8):585–608.
26. Ott PA, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. *Nature.* 2017;547(7662):217–221.
27. Sparano JA, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. *N Engl J Med.* 2018;379(2):111–121.
28. Frampton GM, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat Biotechnol.* 2013;31(11):1023–1031.
29. Amstutz U, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for DPYD genotype and fluoropyrimidine dosing. *Clin Pharmacol Ther.* 2018;103(2):210–216.
30. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. *J Health Econ.* 2016;47:20–33.
31. Vokinger KN, et al. Prices and clinical benefit of cancer drugs in the USA and Europe. *Lancet Oncol.* 2020;21(5):664–670.
32. Holohan C, et al. Cancer drug resistance: an evolving paradigm. *Nat Rev Cancer.* 2013;13(10):714–726.